A closer look at urinary activity and PET radiopharmaceuticals for prostate cancer imaging

At the Society of Nuclear Medicine and Molecular Imaging conference, Phillip Kuo, MD, PhD, FACR, professor at the College of Medicine – Tucson, discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals and new phase 3 study data.